Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 1/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 8/20 | 0.43 |
| ▸ | REN | P00797 | 1/20 | 0.42 |
| ▸ | GNPAT | O15228 | 1/20 | 0.39 |
| ▸ | CTSC | P53634 | 1/20 | 0.39 |
| ▸ | EED | O75530 | 1/20 | 0.39 |
| ▸ | FAAH | O00519 | 1/20 | 0.39 |
| ▸ | MGLL | Q99685 | 1/20 | 0.39 |
| ▸ | LTA4H | P09960 | 1/20 | 0.39 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.39 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.39 |
| ▸ | PSMB9 | P28065 | 1/20 | 0.39 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.39 |
| ▸ | PSMB10 | P40306 | 1/20 | 0.39 |
| ▸ | PSMB2 | P49721 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24312459 | 0.87 | AKT1 (0.45) | AKT1OPRK1GNPATPSMB5 | |
| SCHEMBL28620268 | 0.86 | AKT1 (0.55) | AKT1OPRK1GNPATCTSCFAAH | |
| SCHEMBL28620270 | 0.86 | AKT1 (0.55) | AKT1OPRK1GNPATCTSCFAAH | |
| SCHEMBL24312458 | 0.83 | AKT1 (0.47) | AKT1OPRK1PSMB5 | |
| SCHEMBL31374740 | 0.78 | AKT1 (0.43) | AKT1OPRK1RENGNPATPSMB1 | |
| SCHEMBL29309810 | 0.77 | OPRD1 (0.47) | AKT1OPRK1GNPAT | |
| SCHEMBL23983118 | 0.76 | CDYL2 (0.43) | AKT1 | |
| SCHEMBL21952759 | 0.75 | CTSC (0.52) | OPRK1CTSCLTA4H | |
| SCHEMBL5967176 | 0.75 | CTSC (0.52) | OPRK1CTSCLTA4H | |
| SCHEMBL22207323 | 0.74 | AKT1 (0.69) | AKT1RENPSMB8PSMB9PSMB5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220105194-A1 | CONJUGATE COMPRISING LIGAND, SPACER, PEPTIDE LINKER, AND BIOMOLECULE | ASTELLAS PHARMA INC. (JP) | 2022-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220105194-A1 | CONJUGATE COMPRISING LIGAND, SPACER, PEPTIDE LINKER, AND BIOMOLECULE | MUC1, CA14, CA13 | AKT1 4878/4885OPRK1 3490/4885REN 4446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.